- Wall Street indices open higher
- US2000 attempts to break back above 2,050 pts
- Fastenal drops 5% after Q1 2024 earnings
Wall Street indices launched today's trading higher, recovering part of yesterday's losses. S&P 500 opened 0.2% higher, Dow Jones gained 0.1% at session launch, while Nasdaq and small-cap Russell 2000 jumped 0.3% and 0.4%, respectively. Today's PPI reading did not turn out to be a hawkish surprise like yesterday's CPI print. In fact, headline PPI inflation accelerate less than expected, triggering an uptick on US indices.
Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appRussell 2000 futures (US2000) outperform other US indices today. US2000 is up around 0.5% on the day, erasing a part of yesterday's plunge. Taking a look at US2000 chart at H4 interval, we can see that the index plunged below the 2,075-2,080 pts area yesterday, marked with the previous price reactions, 200-period moving average (purple line) and the lower limit of the bullish channel. A textbook target of the downside breakout from the channel suggest a possibility of a move to as low as 1,995 pts area. However, declines seem to have been halted in the 2,032 pts swing area, at least for now. Should the stock managed to recover back above the 2,050 pts resistance zone, an attempt may be made to return to the bullish channel.
Company News
Fastenal (FAST.US) drops after reporting Q1 2024 earnings ahead of the market open. Company reported 1.9% YoY increase in net sales to $1.90 billion (exp. $1.91 billion). Daily sales climbed 2.1% YoY to $29.6 million (exp. $30 million). Operating income at $390.2 million was 0.8% YoY lower (exp. $404.3 million), while operating margin at 20.6% was lower than 21.2% reported a year ago and also lower than 21.1% expected by the markets. EPS stayed unchanged compared to a year ago at $0.52 (exp. $0.53). Company expects full-year capital expenditures to reach $225-245 million (exp. $222 million).
Vertex Pharmaceuticals (VRTX.US) agreed to acquire Alpine Immune Systems, a kidney drug developer, in a cash transaction. Company will be acquired at $55 per share, or a total of $4.9 billion in cash. Alpine shares surged over 30% to around $64 per share, while Vertex shares held steady. Analysts view the move favorably, saying that Alpine acquisition is a strategic fit for Vertex
Analysts' actions
- Atlassian (TEAM.US) upgraded to 'overweight' at Barclays. Price target set at $275.00
- Nike (NKE.US) upgraded to 'buy' at Bank of America. Price target set at $113.00
- Robinhood Markets (HOOD.US) downgraded to 'sell' at Citi. Price target set at $16.00
- DoorDash (DASH.US) upgraded to 'buy' at MoffetNathanson. Price target set at $164.00
- Albemarle (ALB.US) upgraded to 'buy' at Berenberg. Price target set at $160.00
- Exelixis (EXEL.US) downgraded to 'equal-weight' at Barclays. Price target set at $25.00
- Gen Digital (GEN.US) downgraded to 'equal-weight' at Barclays. Price target set at $25.00
- Kenvue (KVUE.US) rated 'underperform' at Bernstein. Price target set at $18.00
Vertex Pharmaceuticals (VRTX.US) launched today's trading slightly higher, following announcement of Alpine Immune Systems acquisition. Stock climbed to record highs at the turn of January and February 2024, but has struggled since and traded lower. Stock is now trading in a short-term downward channel. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
